

**Amendments to the Claims:**

This listing of claims will replace all prior versions, and listings, of claims in the application:

**Listing of Claims:**

The following list of claims will replace all prior versions and listings of claims in the application.

1-11. (Canceled)

12. (Currently Amended) A method of treating a solid vascularized tumor in a subject in need of such treatment, comprising administering erythropoietin prior to initial administration of ~~a chemotherapeutic agent~~ cisplatin, carboplatin or mitomycin, wherein said erythropoietin is administered in an amount effective to enhance suppression of endothelial growth associated with administration of said ~~chemotherapeutic agent~~ cisplatin, carboplatin or mitomycin, wherein said amount is a dosage in a range of 750 Units per kilogram to 2000 Units per kilogram.

13-18. (Canceled)

19. (Currently Amended) A method according to claim 12 [[15]], wherein said chemotherapeutic agent is administered intravenously.

20. (Currently Amended) A method according to claim 12, wherein said erythropoietin is administered intravenously or subcutaneously.

21. (Currently Amended) A method of treating a solid vascularized tumor in a subject in need of such treatment, comprising administering erythropoietin prior to initial administration of cisplatin;

wherein said erythropoietin is administered in an endothelial-inhibiting amount of, <sup>growth suppressing</sup> wherein said amount is a dosage in a range from about 750 Units per kilogram to about 2,000 Units per kilogram.

22- 23. (Canceled)

<sup>5</sup>  
~~24.~~ (Previously Presented) A method according to claim <sup>4</sup>~~21~~, wherein said cisplatin is administered intravenously.

<sup>6</sup>  
~~25.~~ (Currently Amended) A method according to claim <sup>4</sup>~~21~~, wherein said erythropoietin is administered intravenously or subcutaneously.

<sup>7</sup>  
~~26.~~ (Currently Amended) A method according to claim <sup>4</sup>~~12~~ ~~[[15]]~~, wherein said ~~chemotherapeutic agent~~ cisplatin, carboplatin or mitomycin is administered in a manner selected from the group consisting of intravenous, intramuscular, intraperitoneal, subcutaneous, intratumor, and intrapleural injection.

27-30. (Canceled)

<sup>8</sup>  
~~31.~~ (Previously Presented) A method of treating a solid vascularized tumor according to claim <sup>11</sup>~~34~~, wherein the solid vascularized tumor is a cerebellar hemangioblastoma.

<sup>9</sup>  
~~32.~~ (Previously Presented) A method of treating a solid vascularized tumor according to claim <sup>11</sup>~~34~~, wherein the solid vascularized tumor is a ductal carcinoma of the breast.

<sup>10</sup>  
~~33.~~ (Previously Presented) A method of treating a solid vascularized tumor according to claim <sup>11</sup>~~34~~, wherein the solid vascularized tumor is a squamous cell cancer of the larynx.

<sup>11</sup>  
~~34.~~ (Previously Presented) A method of treating a solid vascularized tumor according to claim <sup>11</sup>~~32~~, wherein said subject is afflicted with a solid vascularized tumor selected from cerebellar hemangioblastoma, ductal carcinoma of the breast or squamous cell cancer of the larynx.

35. (Previously Presented) A method of treating a solid vascularized tumor according to claim 21, wherein said subject is afflicted with a solid vascularized tumor selected from cerebellar hemangioblastoma, ductal carcinoma of the breast, or squamous cell cancer of the larynx.